Современные подходы к фармакотерапии гриппа

1. Centers for Disease Control and Prevention (CDC). Key facts about influenza (flu) and flu vaccine. Revised 2010. Available at: http:// www.cdc.gov/flu/keyfacts.htm. Last accessed 2010.
2. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333–40.
3. Ramet J, Weil-Olivier C, Sedlak W. Influenza vaccination: the paediatric perspective. Vaccine 2007; 25 (5): 780–7. Epub: 2006.
4. Harnden A, Brueggemann A, Shepperd S et al. Near patient testing for influenza in children in primary care: comparison with laboratory test. BMJ 2003; 326 (7387): 480.
5. Klein TW, Newton C, Larsen K et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486–9.
6. Raznikov V, Gazumyan A, Nikitenko A et al. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol 2001; 8: 645–59.
7. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO: 2010. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_11_19/en/index.html. Last accessed 2010.
8. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708–19.
9. World Health Organization (WHO). Pandemic (H1N1) 2009 – update 112. 2010. Available at: http://www.who.int/csr/don/ 2010_08_06/en/ index.html. Last accessed 2010.
10. Иммунопрофилактика-2007. Справочник. Под ред. В.К.Таточенко, Н.А.Озерцковского М.: Континент-Пресс, 2007.
11. Brooks MJ, Burtseva EI, Ellery PJ et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012; 84 (1): 170–81.
12. Справочник поликлинического врача. 2010; 9: 1–6.
13. Thorlund K et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011; 11: 134.
14. World Health Organization (WHO). WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised 2010. Available at: http://www.who.int/csr/resources/publications/ swineflu/h1n1_use_antivirals_20090820/en/index. html. Last accessed 2010.
15. Health Protection Agency. Pharmacologicial treatment and prophylaxis of influenza. Version 1.7. Available at: http://www.hpa.org.uk/web/ HPAwebFile/HPAweb_C/ 1287147812045. Last accessed 2011.
16. Smith JR, Rayner CR, Donner B et al. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 2011; 28 (11): 927–59.
17. Adisasmito W, Chan PK, Lee N et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202: 1154–60.
18. Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin Pharmacol Ther 2010; 88: 704–7.
19. Acosta EP, Jester P, Gal P et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202: 563–6.
20. Aoki F, Lam H, Jeffrey JR, Sitar DS. Oseltamivir does not interact pharmacokinetically with cyclosporine, mycophenolate or tacrolimus in renal transplant patients. Annual Meeting of the Infectious Disease Society of America. San Francisco, CA, USA. 2005 Abstract.
21 Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–24.
22. Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667–72.
23. Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54.
24. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127–33.
25. Winther B, Block SL, Reisinger K, Dutkowski R. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int J Pediatr Otorhinolaryngol 2010; 74: 684–8.
26. Reisinger K, Marcadis I, Cupelli LA, Shu D. Oseltamivir for prevention of seasonal influenza in children. Options for the Control of Influenza VI. Toronto, Canada. 2007. Abstract.
27. Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44: 197–202.
28. Sugaya N, Tamura D, Yamazaki M et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47: 339–45.
29. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007; 23: 523–31.
30. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124: 170–8.
31. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000–2005. Medscape J Med 2008; 10: 131.
32. McGeer A, Green KA, Plevneshi A et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568–75.
33. Lee N, Choi KW, Chan PK et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510–15.
34. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007; CD002744.
35. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106.
36. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53: 277–9.
37. Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51: 887–94.
38. Writing Committee of the Second World Health Organization Consultationon Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358: 261–73.
39. Smith JR. Oseltamivir in human avian influenza infection. J Antimicrob Chemother 2010; 65 (Suppl. 2): ii25–33.
40. Li IW, Hung IF, To KK et al. The natural viral load profile of patients with pandemic swine-origin influenza A H1N1 2009 (pH1N1) and the effect of oseltamivir treatment. Chest 2010; 137: 759–68.
41. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50: 963–9.
42. Jain S, Kamimoto L, Bramley AM et al. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935–44.
43. Dominguez-Cherit G, Lapinsky SE, Macias AE et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302: 1880–7.
44. Chien YS, Su CP, Tsai HT et al. Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. J Infect 2010; 60: 168–74.
45. Centers for Disease Control and Prevention. Patients hospitalized with 2009 pandemic influenza A (H1N1). New York City, 2009. MMWR Morb Mortal Wkly Rep 2010; 58: 1436–40.
46. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362: 27–35.
47. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 521–6.
48. Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896–902.
49. Torres JP, O’Ryan M, Herve B et al. Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin Infect Dis 2010; 50: 860–8.
50. Komiya N, Gu Y, Kamiya H et al. Household transmission of pandemic 2009 influenza a (H1N1) virus in Osaka, Japan in May 2009. J Infect 2010; 61: 284–8.
51. Leung YH, Li MP, Chuang SK. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. Epidemiol Infect 2011; 139: 41–44.
52. van der Vries E, Veldhuis Kroeze EJ et al. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog 2011; 7 (9): e1002276.
53. Coffin SE, Leckerman K, Keren R et al. Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J 2011; 30 (11): 962–6.
54. Vavricka CJ, Li Q, Wu Y et. al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza na inhibition. PLoS Pathog 2011; 7 (10): e1002249.
55. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12: 603–16.
56. Dharan NJ, Gubareva LV, Meyer JJ et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301: 1034–41.
57. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–2008. Emerg Infect Dis 2009; 15: 155–62.
58. L'vov DK, Burtseva EI, Lavrishcheva VV. Information of the Center for Ecology and Epidemiology of Influenza, D. I. Ivanovsky Research Institute of Virology, Russian Academy of Medical Sciences, on the results of the 2009–2010 influenza and acute respiratory viral infection epidemic season (at week 40 of 2009 to week 22 of 2010) in the world and Russia. Vopr Virusol 2011; 56 (1): 44–9.
59. Okomo-Adhiambo M, Sleeman K, Ballenger K et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2010; 2 (10): 2269–89. Epub: 2010.
60. Thorlund K et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011; 11: 134.
61. Redlberger-Fritz M et al. Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis 2011[Epub ahead of print].
62. Dutkowski R, Thakrar B, Froehlich E et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003; 26: 787–801.
63. Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440–9.
64. Reisinger K, Cupelli LA, and Shu D. Seasonal prophylaxis of influenza with oseltamivir in children. 5th Annual Meeting of the World Society for Paediatric Infectious Diseases (WSPID). Bangkok, Thailand. 2007. Abstract.
65. Khandaker G, Zurynski Y, Lester-Smith D et. al. Clinical features, oseltamivir treatment and outcome in infants aged <12 months with laboratory-confirmed influenza A in 2009. Antivir Ther 2011; 16 (7): 1005–10.
66. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother 2011; 17 (5): 595–601.
67. European Medicines Evaluation Agency (EMEA). Assessment report for Tamiflu. London, 24 September 2009. Available at: http://www.emea. europa.eu/docs/en_GB/document_library/ EPAR_-_ Assessment_Report_-_Variation/human/000402/ WC500033109.pdf. Last accessed 2010.
68. Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents 2010; 35: 461–7.
69. Postma MJ, Beardsworth P, Wilschut JC. Cost effectiveness of oseltamivir treatment of influenza:a critique of published methods and outcomes. J Med Econ 2008; 11: 743–68.
70. Nagase H, Moriwaki K, Kamae M, Yanagisawa S, Kamae I. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. Value Health 2009; 12 (Suppl. 3): S62–5.
71. Sugaya N, Kohno S, Ishibashi T et al. Efficacy, Safety, and Pharmacokinetics of Intravenous Peramivir in Children with 2009 Pandemic A (H1N1) Influenza Virus Infection. Antimicrob Agents Chemother 2011 [Epub ahead of print].
72. Atiee G, Lasseter K, Baughman S et. al. Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans. J Clin Pharmacol 2011 [Epub ahead of print].
73. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimic­rob Agents Chemother 2011; 55 (11): 5267–76.
74. Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011; 9 (10): 851–7.
75. Kim WY, Young Suh G, Huh JW et al. Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation. Antimic­rob Agents Chemother 2011; 55 (12): 5703–9.
76. Fukuoka M, Minakuchi M, Kawaguchi A et al. Structure-based discovery of anti-influenza virus A compounds among medicines. Biochim Biophys Acta 2011 [Epub ahead of print].

А.С.Дарманян

Научный центр здоровья детей РАМН, Москва